GB 262
Alternative Names: GB-262; PD-L1×CD55 bi-specific antibody - Genor BiopharmaLatest Information Update: 03 Apr 2025
At a glance
- Originator Genor Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD55 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Mar 2025 Preclinical development is ongoing China (Genor Biopharma pipeline, March 2025)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 10 Apr 2021 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)